Literature DB >> 25175766

Allogenic mesenchymal stem cells as a treatment for equine degenerative joint disease: a pilot study.

Sarah Broeckx, Marc Suls, Charlotte Beerts, Aurélie Vandenberghe, Bert Seys, Karin Wuertz-Kozak, Luc Duchateau, Jan H Spaas1.   

Abstract

Cell-based therapies, such as treatments with mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) are thought to have beneficial effects on the clinical outcome of orthopedic injuries, but very few animal studies with large sample size are published so far. Therefore, the aim of this study was to assess the safety and report the clinical outcome of allogenic, immature or chondrogenic induced MSCs in combination with PRP for the treatment of degenerative joint disease (DJD) in 165 horses. MSCs and PRP were isolated from a 6-year-old donor horse and transplanted either in their native state or after chondrogenic induction in combination with PRP into degenerated stifle (n=30), fetlock (n=58), pastern (n=34) and coffin (n=43) joints. Safety was assessed by means of clinical evaluation and the outcome was defined as failure to return to work (score 0), rehabilitation (score 1), return to work (score 2) and return to previous level (score 3), shortly (6 weeks) after treatment or at 18 weeks for the patients that returned for long-term follow-up (n=91). No adverse effects were noticed, except for three patients who showed a moderate flare reaction within one week after treatment of the fetlock joint without long-term effects (1.8% of 165 horses). Already after 6 weeks, 45% (native MSCs) and 60% (chondrogenic induced MSCs) of the treated patients returned to work (→ score 2+3) and the beneficial effects of the treatment further increased after 18 weeks (78% for native MSCs and 86% for chondrogenic induced MSCs). With the odds ratio of 1.47 for short-term and 1.24 for long-term, higher average scores (but statistically not significant) could be noticed using chondrogenic induced MSCs as compared to native MSCs. For all three lower limb joints a higher percentage of the treated patients returned to work after chondrogenic induced MSC treatment, whereas the opposite trend could be noticed for stifle joints. Nevertheless, more protracted follow-up data should confirm the sustainability of these joints.

Entities:  

Mesh:

Year:  2014        PMID: 25175766     DOI: 10.2174/1574888x09666140826110601

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  17 in total

1.  Persistence of fluorescent nanoparticle-labelled bone marrow mesenchymal stem cells in vitro and after intra-articular injection.

Authors:  Sicilia T Grady; Lorraine Britton; Katrin Hinrichs; Alan J Nixon; Ashlee E Watts
Journal:  J Tissue Eng Regen Med       Date:  2019-01-23       Impact factor: 3.963

2.  Tenogenic induction of equine mesenchymal stem cells by means of growth factors and low-level laser technology.

Authors:  Chiara Gomiero; Giulia Bertolutti; Tiziana Martinello; Nathalie Van Bruaene; Sarah Y Broeckx; Marco Patruno; Jan H Spaas
Journal:  Vet Res Commun       Date:  2016-01-13       Impact factor: 2.459

Review 3.  Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders.

Authors:  Mohamad Al Naem; Lynda Bourebaba; Katarzyna Kucharczyk; Michael Röcken; Krzysztof Marycz
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

4.  Utility of a Mouse Model of Osteoarthritis to Demonstrate Cartilage Protection by IFNγ-Primed Equine Mesenchymal Stem Cells.

Authors:  Marie Maumus; Gautier Roussignol; Karine Toupet; Geraldine Penarier; Isabelle Bentz; Sandrine Teixeira; Didier Oustric; Mireille Jung; Olivier Lepage; Regis Steinberg; Christian Jorgensen; Danièle Noel
Journal:  Front Immunol       Date:  2016-09-27       Impact factor: 7.561

5.  Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.

Authors:  Laura Barrachina; Ana Rosa Remacha; Antonio Romero; Arantza Vitoria; Jorge Albareda; Marta Prades; Mercedes Roca; Pilar Zaragoza; Francisco José Vázquez; Clementina Rodellar
Journal:  BMC Vet Res       Date:  2018-08-17       Impact factor: 2.741

6.  Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses.

Authors:  Sarah Y Broeckx; Bert Seys; Marc Suls; Aurélie Vandenberghe; Tom Mariën; Edouard Adriaensen; Jeroen Declercq; Lore Van Hecke; Gabriele Braun; Klaus Hellmann; Jan H Spaas
Journal:  Stem Cells Dev       Date:  2019-02-13       Impact factor: 3.272

7.  Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.

Authors:  Aimée C Colbath; Steven W Dow; Leone S Hopkins; Jennifer N Phillips; C Wayne McIlwraith; Laurie R Goodrich
Journal:  Equine Vet J       Date:  2020-02-14       Impact factor: 2.888

8.  Tenogenically Induced Allogeneic Mesenchymal Stem Cells for the Treatment of Proximal Suspensory Ligament Desmitis in a Horse.

Authors:  Aurélie Vandenberghe; Sarah Y Broeckx; Charlotte Beerts; Bert Seys; Marieke Zimmerman; Ineke Verweire; Marc Suls; Jan H Spaas
Journal:  Front Vet Sci       Date:  2015-10-22

Review 9.  Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.

Authors:  Sophie Helen Bogers
Journal:  Front Vet Sci       Date:  2018-04-16

Review 10.  Veterinary Regenerative Medicine for Musculoskeletal Disorders: Can Mesenchymal Stem/Stromal Cells and Their Secretome Be the New Frontier?

Authors:  Michela Mocchi; Silvia Dotti; Maurizio Del Bue; Riccardo Villa; Elia Bari; Sara Perteghella; Maria Luisa Torre; Stefano Grolli
Journal:  Cells       Date:  2020-06-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.